aadibio.com - WHWK Net Assets per Single Share

Public company logo of Aadi Bioscience Inc (WHWK)

Aadi Bioscience Inc (WHWK) develops targeted therapies for rare tumors via its Nab platform and the drug Fyarro, establishing a unique niche in the treatment of mTOR-dependent cancers. The book value per share on this GURU.Markets chart reflects asset dynamics, where 3.24 determines the current metric. The operating model relies on GMP-standard manufacturing outsourcing through external partners.

Aadi Bio (WHWK) - Accounting Value per Share from 03/20/2025 to 10/27/2026

Summary analytical data breakdowns for Aadi Bioscience, Inc. (WHWK)

- price and consensus price forecast:
Stock Quotes Aadi Bio|WHWK - Consensus Target
- market capitalization data:
Market Value Aadi Bioscience Inc|WHWK - Enterprise Value
- book capitalization data:
Book Value per Share Aadi Bioscience|WHWK - Company Net Assets|Market Capitalization to Book Value Ratio aadibio.com|WHWK - Company Total Assets
- debt and liquidity data:
Debt to Equity Aadi Bioscience Inc|WHWK - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Aadi Bio|WHWK - Company Total Debt|Debts to Book Capitalization Aadi Bioscience Inc
Analysis of all company metrics:aadibio.com, WHWK
Manufactured product of Aadi Bioscience, Inc.

For Aadi Bioscience Inc (WHWK), the book value per share serves as an indicator of the residual value of net assets, which is critical when clinical programs are scaled back and pipeline prospects are limited. The current value of 3.24, reflected through the calculated book value per share, demonstrates the company's fundamental basis; however, investors should consider the risk of capital impairment in the absence of stable cash flow.

Competitor analysis for Aadi Bioscience Inc

ONC: Accounting Value per Share|HALO: Accounting Value per Share|RVMD: Net Assets per Single Share|ascentage.com (AAPG) - Book Value per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com|Book Value per Share ARTV|Book Value per Share adlainortye.com (ANL)|Book Value per Share VERU (Veru)|Book Value per Share Tempest Therapeutics Inc TPST|Xilio (XLO) - Book Value per Share|RENB - Equity per Share|muraloncology.com - Book Value per Share|Net Assets per Share Kairos Pharma|OKUR - Accounting Value per Share|Accounting Value of a Share CytoMed|Book Value per Share Curis, Inc. (CRIS)|Net Assets per Single Share apollomicsinc.com (APLM)|Book Value per Share THAR|Advanced Biomed Inc. - Net Assets per Share|GNPX (Genprex) - Net Assets per Single Share|CLDI: Net Asset Value per Share|Sunshine Biopharma, Inc. - Net Assets per Single Share|Xenetic Biosciences, Inc. (XBIO) - Net Assets per Share|Book Value per Share SLRX|Accounting Value per Share purple-biotech.com|AONC (American Oncology Network) - Book Value per Share|Net Assets per Share BeiGene Ltd. (BGNE)|CKPT: Book Value per Share|elevationoncology.com - Net Asset Value per Share|iCAD Corp (ICAD) - Net Assets per Single Share|IKNA - Equity per Share|NTBL (Notable Labs) - Book Value per Share|Viracta Therapeutics, Inc. (VIRX) - Accounting Value per Share|Book Value per Share MOR (MorphoSys Corp)|Net Asset Value per Share NAYA Biosciences Corp (NAYA)|Ascentage Pharma Group (AAPGV) - Accounting Value per Share